Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33
Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and lowers the price target from $36 to $33.
Stocks · News reference
Analysts cut targets for GWW, IE and COST, while raising targets for OKTA, AXGN, ZS and DRI; ratings remained unchanged.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and lowers the price target from $36 to $33.
BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $36 to $34.
Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $41 to $35.
AMD reached a $1 trillion market cap, joining Nvidia in an exclusive club. However, the article argues AMD is overvalued as a distant second in the AI accelerator market. While AMD has secured major deals with OpenAI, Meta, Anthropic, Oracle, and Microsoft, its data center revenue ($6.7B quarterly) significantly lags Nvidia's ($89B quarterly). AMD trades at a P/E of 158 (forward: 81) versus Nvidia's 28 (forward: 24), suggesting investors are paying a premium for inferior market position and thinner margins.
B of A Securities analyst Vivek Arya maintains Advanced Micro Devices (NASDAQ:AMD) with a Buy and raises the price target from $620 to $720.
AMD stock gains 2% premarket following a technical breakout above key resistance. Analysts target up to $750 as AI momentum grows.